MAXHEALTH: 1–2 Week Trade View hero image

Quick answer: MAXHEALTH is a wait, not a buy at market. The better setups are a daily close above INR 1,064 on at least 2.40 million shares or a bullish reversal from INR 1,036-1,044. A daily close below INR 1,014 invalidates the long setup.

Wealth.ai Market Desk

MAXHEALTH: 1-2 Week Tactical Trade Research

A short swing-trade review built around confirmation, risk and the 28 September event.

WAIT / CONDITIONAL LONG | MEDIUM CONFIDENCE

INR 1,051.5021 Sep, 10:29 IST

57.47Wilder RSI(14)

INR 1,064Breakout trigger

28 SepKalinga hearing

Decision: MAXHEALTH is worth monitoring, but the entry around INR 1,051-1,052 is weak. Price is pressing into INR 1,060-1,064 resistance after a fast rebound. Wait for proof rather than buying the intraday spike.

Data cut-off

Instrument: Max Healthcare Institute Ltd (NSE: MAXHEALTH).

Intraday Yahoo quote at 10:29 IST on 21 September 2026: INR 1,051.50.
Intraday range at that time: INR 1,051.10-INR 1,063.80.
Latest completed session: 18 September close at INR 1,049.30.
Daily indicators exclude the partial 21 September candle and its incomplete volume.

Technical evidence

Indicator	Reading	What it says
Moving averages	SMA5 1,035.80; SMA10 1,022.49; SMA20 1,014.67; SMA50 1,048.90; SMA100 1,045.76; SMA200 1,038.23	The completed close is above every average, but only just above the 50- and 100-day lines. The trend is repairing, not fully established.
RSI(14)	57.47	Positive momentum without an overbought RSI reading.
MACD	-0.54 vs signal -7.50; histogram +6.97	A bullish crossover supports the rebound, although MACD remains just below zero.
Stochastic %K	87.66	The short rebound is stretched, so chasing resistance carries pullback risk.
Bollinger Band	Upper band INR 1,055.11	Price tested above the band intraday. A strong close is needed to separate expansion from rejection.
ATR(14)	INR 23.75, or 2.26%	A normal daily move is large enough to hit tight stops.
Volume	2.10m vs 1.92m 20-session average	Participation was 1.09x average. Constructive, but short of the chosen 2.40m breakout threshold.

Relative strength

Window	MAXHEALTH	Read-through
5 sessions	+1.03%	Modest positive momentum.
10 sessions	+5.47%	The rebound accelerated.
20 sessions	+5.15%	MAXHEALTH beat Fortis (-2.78%) and Apollo Hospitals (+2.40%).
60 sessions	-3.00%	The broader correction has not been fully reversed.

On common trading dates, MAXHEALTH outperformed the Nifty 50 by about 8.80 percentage points over 20 sessions. Annualized volatility over 60 completed sessions was 25.71%. Recent leadership is real, but it is still a short-term signal.

Decision levels

Level	Zone	Interpretation
Breakout resistance	INR 1,060-1,064	A close above this zone must be backed by volume.
Immediate support	INR 1,046-1,050	The 50- and 100-day averages converge here.
Better pullback support	INR 1,036-1,040	The 5- and 200-day averages converge here.
Long-thesis invalidation	Daily close below INR 1,014	Trend repair has failed. Lower references are INR 995 and INR 974.

Trade scenarios

1. Preferred: breakout long

Trigger: Daily close above INR 1,064.
Confirmation: Full-session volume of at least 2.40 million shares, with the close preferably in the upper third of the day's range.
Entry: INR 1,065-1,070 only if INR 1,064 holds on the following session. Do not chase a large gap.
Closing stop: INR 1,044. Exit sooner if a breakout immediately closes back below INR 1,060.
Targets: INR 1,088 and INR 1,112.
Reward/risk: At an illustrative INR 1,067 fill, about 0.9R to target 1 and 2.0R to target 2.

2. Alternative: pullback reversal

Trigger zone: INR 1,036-1,044.
Confirmation: A bullish reversal candle, stronger intraday breadth or a reclaim of the prior session high. Do not buy while price is falling.
Illustrative entry: Near INR 1,041 after reversal confirmation.
Closing stop: INR 1,024.
Targets: INR 1,064 and INR 1,088.
Reward/risk: About 1.4R and 2.8R.

3. No-trade zone

If price stays between INR 1,045 and INR 1,064 without confirmed volume, stay out. Support is close enough to be tested while resistance limits immediate upside.

4. Bearish invalidation

A daily close below INR 1,014 invalidates the tactical long thesis. Do not average down. A breakdown could expose INR 995 and INR 974. This review does not recommend an unhedged short.

Position sizing

Use a fixed loss budget rather than a fixed share count:

shares = maximum rupee risk / (entry price - stop price)

An INR 1,067 entry with an INR 1,044 stop risks INR 23 per share. A maximum planned loss of INR 2,300 allows 100 shares before fees and slippage.

The 28 September hearing creates gap risk. A stop order cannot guarantee the stated exit price. As a general rule, limiting planned loss to 0.5%-1% of trading capital is more prudent than relying on the stop alone.

Catalysts and event risk

Constructive factors

Q1 FY27 gross revenue increased 16% year on year to INR 2,982 crore. Operating EBITDA rose 15% to INR 704 crore. Occupancy was 75%, occupied bed days rose 10%, and ARPOB increased 5%.
The 400-bed Max Smart Saket tower was inaugurated on 3 September. Its ramp-up can support earnings, though the announcement is already known.
Management expects a previously agreed 6% insurance-price revision during September-October, but did not give a precise implementation date.
August broker reports remained positive. Anand Rathi retained Buy with an INR 1,220 target, while Motilal Oswal retained Buy with INR 1,410. These are long-term valuation targets, not swing-trade targets.

Risks

The next disclosed NCLT hearing in the Kalinga Hospital dispute is scheduled for 28 September. Its financial effect is unquantified, and the event can cause a gap beyond any stop.
Q1 PAT grew only 3% year on year and fell 8% sequentially. Net debt increased from INR 1,908 crore to INR 2,384 crore, while DSO increased from 87 to 95 days.
Alps Hospital received a GST show-cause notice. It is not an adjudicated liability, but it remains a sentiment risk.
TTM P/E was about 70.6x when reviewed. That valuation increases sensitivity to execution disappointments.
Domestic institutions added shares in the June quarter while foreign institutions reduced holdings by almost the same amount. This was rotation, not broad accumulation.
This review found no dependable fresh September analyst upgrade, credible acquisition rumor or recent material promoter transaction.

Sentiment: 56/100

The tone is mildly positive, not strong. Capacity additions and operating growth support the story. Litigation and tax issues offset part of that strength. August broker ratings were positive, but no fresh September revision was verified. Social and short-interest evidence was too weak to score directionally, so it was treated as neutral.

Bottom line

MAXHEALTH is tradeable only after confirmation. The better setup is a volume-backed close above INR 1,064. A pullback into INR 1,036-1,044 can offer better reward/risk, but only after a clear reversal.

The 28 September Kalinga hearing is the main event risk. Traders who do not accept overnight gap risk should reduce or close exposure before that date rather than assuming a stop will protect them.

Frequently asked questions

Is MAXHEALTH a buy at the reviewed price?

No. The stance is wait or conditional long. The price is close to resistance and needs either a confirmed breakout or a supported pullback reversal.

What confirms the breakout?

A daily close above INR 1,064 with at least 2.40 million shares traded. The next session should also hold the breakout level.

What invalidates the trade?

A completed daily close below INR 1,014 invalidates the tactical long thesis.

What is the main event risk?

The disclosed Kalinga Hospital NCLT hearing on 28 September. Its financial effect is not yet quantified, and it can create overnight gap risk.

Sources

Educational market research only, not individualized financial advice. Prices can gap, indicators can fail, and actual fills may differ materially from the stated levels.

Search This Blog

wealth.ai